Senseonics Holdings (SENS) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this medical technology company would post a loss of $0.03 per share when it actually produced a loss of $0.02, delivering a surprise of 33.33%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Senseonics, which b ...

Company Performance - 10x Genomics reported a quarterly loss of $0.36 per share, better than the Zacks Consensus Estimate of a loss of $0.45, and an improvement from a loss of $0.50 per share a year ago, representing an earnings surprise of 20% [1] - The company posted revenues of $154.88 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 16.24%, and up from $141.01 million in the same quarter last year [2] - Over the last four quarters, 10x Genomics has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - 10x Genomics shares have declined approximately 42.1% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.37 on revenues of $146.51 million, and for the current fiscal year, it is -$1.47 on revenues of $609.56 million [7] Industry Outlook - The Medical Info Systems industry, to which 10x Genomics belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of 10x Genomics may be influenced by the overall industry outlook, as empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions [5][8]

Group 1: Earnings Performance - Enovis reported quarterly earnings of $0.81 per share, exceeding the Zacks Consensus Estimate of $0.74 per share, and up from $0.50 per share a year ago, representing an earnings surprise of 9.46% [1] - The company posted revenues of $558.83 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.03%, and an increase from $516.27 million year-over-year [2] - Over the last four quarters, Enovis has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - Enovis shares have declined approximately 22% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at $0.74 for the coming quarter and $3.19 for the current fiscal year [4][7] - The current Zacks Rank for Enovis is 3 (Hold), indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical Info Systems industry, to which Enovis belongs, is currently in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

Core Viewpoint - Privia Health (PRVA) reported quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.06 per share, representing a 50% earnings surprise [1][6] - The company posted revenues of $480.1 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 5.37% and showing a year-over-year increase from $415.24 million [2] Group 1: Earnings Performance - Privia Health's earnings of $0.03 per share for the recent quarter is an increase from $0.02 per share a year ago, but still below expectations [1] - The company has not surpassed consensus EPS estimates over the last four quarters [2][6] Group 2: Revenue Performance - The reported revenue of $480.1 million for the quarter represents a 15.6% increase compared to the previous year's revenue of $415.24 million [2] - Privia Health has exceeded consensus revenue estimates in all four quarters over the past year [2] Group 3: Stock Performance and Outlook - Privia Health shares have increased by approximately 19.3% since the beginning of the year, contrasting with a decline of 4.3% in the S&P 500 [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] Group 4: Earnings Estimates and Industry Outlook - The current consensus EPS estimate for the upcoming quarter is $0.06 on revenues of $461.1 million, and for the current fiscal year, it is $0.24 on revenues of $1.88 billion [7] - The Medical Info Systems industry, to which Privia Health belongs, is currently ranked in the top 32% of Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Group 1 - TruBridge reported quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.37 per share, but showing an increase from $0.19 per share a year ago, resulting in an earnings surprise of -2.70% [1] - The company posted revenues of $87.21 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.51%, and compared to year-ago revenues of $83.25 million [2] - TruBridge has topped consensus revenue estimates four times over the last four quarters, indicating a consistent performance in revenue generation [2] Group 2 - The stock has increased approximately 29.1% since the beginning of the year, contrasting with the S&P 500's decline of -4.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.28 on revenues of $87.33 million, and for the current fiscal year, it is $1.79 on revenues of $349.64 million [7] Group 3 - The Medical Info Systems industry, to which TruBridge belongs, is currently in the top 27% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - The Zacks Rank for TruBridge is currently 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6]

Company Performance - Schrodinger, Inc. reported a quarterly loss of $0.82 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.71, and compared to a loss of $0.76 per share a year ago, indicating a negative earnings surprise of -15.49% [1] - The company posted revenues of $59.55 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 6.81%, and showing significant growth from year-ago revenues of $36.6 million [2] - Over the last four quarters, Schrodinger has surpassed consensus revenue estimates three times, but has only exceeded EPS estimates once [2] Stock Outlook - Schrodinger shares have increased approximately 22.1% since the beginning of the year, contrasting with a -4.7% decline in the S&P 500 [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.76 for the coming quarter and -$2.47 for the current fiscal year [4][7] - The estimate revisions trend for Schrodinger is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical Info Systems industry, to which Schrodinger belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Company Performance - Outset Medical, Inc. reported a quarterly loss of $3.24 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.97, representing an earnings surprise of -234.02% [1] - The company posted revenues of $29.75 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 7.49%, and showing an increase from $28.17 million in the same quarter last year [2] - Over the last four quarters, Outset Medical has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Outset Medical shares have declined approximately 30.7% since the beginning of the year, in contrast to the S&P 500's decline of -4.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.95 on revenues of $29.5 million, and for the current fiscal year, it is -$3.92 on revenues of $120.09 million [7] Industry Outlook - The Medical Info Systems industry, to which Outset Medical belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]

While Clover Health Investments has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Clover Health Investments, Corp. (CLOV) came out with quarterly ear ...

Group 1 - Standard BioTools reported a quarterly loss of $0.04 per share, which is an improvement from a loss of $0.23 per share a year ago, aligning with the Zacks Consensus Estimate [1] - The company posted revenues of $40.8 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.73%, but down from $45.54 million year-over-year [2] - Standard BioTools shares have declined approximately 34.3% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] Group 2 - The earnings outlook for Standard BioTools is mixed, with current consensus EPS estimates at -$0.05 for the coming quarter and -$0.16 for the current fiscal year, with revenues expected at $38.9 million and $169.2 million respectively [7] - The Zacks Industry Rank indicates that the Medical Info Systems sector is in the top 28% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Group 1 - American Well Corporation (AMWL) is performing better than the Medical sector with a year-to-date return of approximately 0.8%, while the sector has lost an average of 2.4% [4] - The Zacks Rank for American Well Corporation is 2 (Buy), indicating a favorable outlook based on earnings estimate revisions [3] - The Zacks Consensus Estimate for AMWL's full-year earnings has increased by 5.7% in the past quarter, reflecting improved analyst sentiment [4] Group 2 - American Well Corporation is part of the Medical Info Systems industry, which consists of 38 stocks and currently ranks 69 in the Zacks Industry Rank [6] - Stocks in the Medical Info Systems industry have gained about 8.4% year-to-date, indicating that AMWL is slightly underperforming its industry [6] - Claritev Corporation (CTEV), another stock in the Medical sector, has shown a year-to-date return of 44.6% and also holds a Zacks Rank of 2 (Buy) [5]